These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Analysis of infection in B-cell lymphoma patients treated with BTK inhibitors]. Wang CM; Liu H; Li LJ; Song J; Wang HQ; Wu YH; Guan J; Xing LM; Wang GJ; Liu H; Qu W; Wang XM; Shao ZH; Fu R Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):582-586. PubMed ID: 37749040 [No Abstract] [Full Text] [Related]
43. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. Nixon S; Duquette D; Doucette S; Larouche JF Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435 [TBL] [Abstract][Full Text] [Related]
44. Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia. Kulumani Mahadevan LS; Ozdemirli M BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34580127 [TBL] [Abstract][Full Text] [Related]
45. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia. Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880 [TBL] [Abstract][Full Text] [Related]